D.E. Shaw & Co
HBIO icon

D.E. Shaw & Co’s Harvard Bioscience HBIO Stock Holding History

D.E. Shaw & Co’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,557
Closed -$237K – 4613
2022
Q4 		$237K Sell
8,557
-15
-0.2% -$370 ﹤0.01% 4178
2022
Q3 		$220K Buy
8,572
+4,503
+111% +$149K ﹤0.01% 4435
2022
Q2 		$146K Buy
+4,069
New +$184K ﹤0.01% 4649
2017
Q3 		– Sell
-2,953
Closed -$75K – 3501
2017
Q2 		$75K Sell
2,953
-4,632
-61% -$115K ﹤0.01% 3285
2017
Q1 		$197K Sell
7,585
-133
-2% -$3.83K ﹤0.01% 3129
2016
Q4 		$235K Buy
7,718
+123
+2% +$3.13K ﹤0.01% 3215
2016
Q3 		$207K Buy
7,595
+651
+9% +$18.1K ﹤0.01% 3188
2016
Q2 		$199K Buy
6,944
+506
+8% +$16.1K ﹤0.01% 3189
2016
Q1 		$194K Buy
6,438
+897
+16% +$25.4K ﹤0.01% 3197
2015
Q4 		$192K Buy
5,541
+4,159
+301% +$142K ﹤0.01% 3570
2015
Q3 		$52K Sell
1,382
-540
-28% -$25.1K ﹤0.01% 3661
2015
Q2 		$110K Sell
1,922
-1,383
-42% -$78.7K ﹤0.01% 3653
2015
Q1 		$192K Buy
3,305
+2,285
+224% +$123K ﹤0.01% 3454
2014
Q4 		$58K Buy
+1,020
New +$48.6K ﹤0.01% 3933
2013
Q3 		– Sell
-1,858
Closed -$67K – 4355
2013
Q2 		$67K Buy
+1,858
New +$71.1K ﹤0.01% 3901

Other funds holding HBIO

2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

D.E. Shaw & Co's HBIO Position: Q1 2023 in Review

D.E. Shaw & Co sold out of Harvard Bioscience (HBIO) in Q1 2023, closing a stake of 8,557 shares — an estimated $237K sold.

D.E. Shaw & Co first reported a position in HBIO in Q2 2013 and held it in 15 quarters. The position peaked at $237K in Q4 2022. 65 funds tracked by Wall St. Rank hold HBIO as of Q1 2023.

  • D.E. Shaw & Co reported no remaining Harvard Bioscience position as of Q1 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 8,557 Harvard Bioscience shares in Q1 2023, an estimated $237K.
  • D.E. Shaw & Co first reported a position in Harvard Bioscience in Q2 2013 and held it in 15 quarters.
  • D.E. Shaw & Co's Harvard Bioscience position peaked at $237K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.